
The Weekly Roundup: November 12-17
ICYMI, this week we had articles about coverage from the American College of Allergy, Asthma and Immunology 2023 Annual Scientific Meeting, the availability of UCB's bimekizumab, FDA breakthrough therapy designation to QTORIN rapamycin for microcystic lymphatic malformations, and more.
Abby L. Allen, RN, NP: Update on Biologics for Atopic Dermatitis
What are some of the challenges and triumphs in using biologics for atopic dermatitis? Abby L. Allen, RN, NP, shares insights at the American College of Allergy, Asthma and Immunology 2023 Annual Scientific Meeting.
Promising Results for Roflumilast Cream 0.15% From the INTEGUMENT Phase 3 Trials
A poster presented at the American College of Allergy, Asthma and Immunology (ACAAI) 2023 Annual Scientific Meeting found once daily roflumilast cream 0.15% safely and significantly improved atopic dermatitis.
Efficacy and Safety Data for Leukotriene Receptor Antagonists for Chronic Urticaria Presented at ACAAI
Late-breaking data adds important safety and efficacy data for leukotriene receptor antagonists augmentation in chronic urticaria treatment.
Award Recipient to Focus on Atopic Dermatitis in Native Americans
Kamran H. Imam, MD, hopes to unlock insights into the atopic disease burden among Native American populations.
Marcella R. Aquino, MD, FACAAI: Don’t Make a Rash Dx
Marcella R. Aquino details issues in differential diagnosis for rashes that mimic allergic skin conditions at the ACAAI Annual Meeting.
Exploring the Diagnostics of Urticaria at ACAAI
Session at the American College of Allergy, Asthma and Immunology (ACAAI) 2023 Annual Scientific Meeting explored issues in understanding and testing for physical urticaria.
Derm In The News: November 5-11
Keep up with the latest headlines in dermatology from the past week, including the rise of teledermatology platforms leading patients to opt out of in-person consultations, WHO and ILO estimates of non-melanoma skin cancer deaths attributable to outdoor work in the sun, and more.
Pointers With Portela: Understanding Health Insurance
In this week’s Pointers With Portela, the 208SkinDoc reviews medical health insurance on his podcast.
Reflecting on a Year of Meaningful Innovations
2023 has been complete with numerous innovations in the dermatology space, including in atopic dermatitis, psoriasis, alopecia areata, and more.
The Amazingly Wide, Ever-Expanding Reach of Dermatology
Dermatology encompasses cosmetics, unregulated products, OTC drugs, OTC devices, prescription devices, and prescription drugs, whether oral, injectable, or topical.
Tildrakizumab Significantly Improved Work Productivity and More in Patients With Plaque Psoriasis
In addition to improvements in work productivity, tildrakizumab also demonstrated significant efficacy and safety.
UCB's Bimekizumab is Now Available
Bimekizumab is the first dual IL-17 A/F inhibitor to treat moderate-to-severe plaque psoriasis. It launches with a list price of $7,200 per syringe.
Nonablative Lasers Offer a Gentle Approach to Healthy Skin
In honor of National Healthy Skin Month, it is the perfect time to encourage patients to integrate gentle laser treatments into their yearly routine to maintain healthy, radiant skin.
Aging, Acne, and the Armamentarium: Hot Topics From the Science of Skincare Summit
Experts discuss insights and hot topics stemming from this year's Science of Skincare Summit, including upcoming innovations and considerations in dermatology.
No Significant Difference in BMI, Weight Regarding Switching Rates for Patients with Psoriasis
Label warnings may affect the initiation of new treatment and real-world switching patterns for psoriasis patients starting treatment with risankizumab.
Dermatology Community Celebrates Nurse Practitioners This NP Week
Dermatology Times, the SDPA, and more are celebrating the invaluable contributions of nurse practitioners in dermatology this NP Week (November 12-18).
The Journal Digest: November 15
This week’s collection of the latest dermatologic studies covers atypical molluscum contagiosum lesions with a CD30-positive T-cell lymphoid infiltrate, comorbidities in pediatric psoriasis, tralokinumab for adolescents with severe AD, and intralesional bleomycin combined with lidocaine for recalcitrant keloid scars.
Almirall, Absci Partner to Develop AI-Designed Therapies for Dermatologic Conditions
Almirall, Absci Partner to Develop AI-Designed Therapies for Dermatologic Conditions
Revolutionizing Vitiligo Care: Dermatology Experts Offer Insights on Economic Factors
Experts Heather Woolery-Lloyd, MD; Chesahna Kindred, MD, MBA, FAAD; Gary M. Owens, MD; and Renata Block, MMS, PA-C, discuss the evolving landscape of vitiligo, particularly from an economic lens.
FDA Grants Breakthrough Therapy Designation to QTORIN Rapamycin for Microcystic Lymphatic Malformations
There are currently no FDA-approved therapies for the rare, genetic disease.
Frontline Forum Part 1: Topical Therapy for Corticosteroid-Responsive Dermatoses
Experts discuss enhancing patient outcomes, the "mounting mutiny" against topicals, and more.
Majority of Dermatologists in US Prescribe Baricitinib to Patients With Alopecia Areata, Report Shows
Baricitinib is more commonly prescribed by dermatologists for patients with alopecia in the US and is projected to maintain a substantial market lead over ritlecitinib.
Cancer Vaccine Plus Keytruda Improves Survival Without Relapse in Resected Melanoma
Findings from a phase 2 trial showed improvements in relapse-free survival with an mRNA vaccine plus Keytruda compared with Keytruda alone in patients with high-risk resected melanoma.
American Indian/Alaska Native Communities Face Barriers to Dermatologic Care, Disparities, and More
November is Native American Heritage Month. Access to dermatological health care has been a persistent challenge for individuals in the AIAN community.
POLL: What Percent of the Global Population is Estimated to Have Hyperhidrosis?
Hyperhidrosis is not rare. According to the International Hyperhidrosis Society, approximately 385 million people worldwide live with hyperhidrosis.
European Commission Approves Lebrikizumab for Atopic Dermatitis
Germany will be the first country where lebrikizumab will be available for prescription, with a subsequent rollout across European countries throughout 2024.
Purple Heart Project Seeks to Provide Veterans With Access to Dermatologic Care
Jorge Garcia-Zuazaga, MD, MBA, FAAD, FACMS, discusses Apex Dermatology's Purple Heart Project.
Shawn Kwatra, MD, Shares Highlights From the 12th World Congress on Itch
Kwatra presented on the unmet need for itch improvement in patients with skin of color.
To stay up-to-date with the latest dermatology news, sign up to receive our
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.


















